Granisetron (tablet)

{{DrugProjectFormSinglePage |authorTag=Shanshan Cen, M.D. [1] |genericName=Granisetron hydrochloride |aOrAn=an |drugClass=antinauseant and antiemetic agent |indicationType=prevention |indication=nausea and vomiting associated with:1) initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin;2) radiation, including total body irradiation and fractionated abdominal radiation |adverseReactions=asthenia, headache, [[somnolence, and fever |blackBoxWarningTitle=ConditionName: |blackBoxWarningBody=ConditionName:

• Content

|fdaLIADAdult=====Indications==== Granisetron hydrochloride tablets are indicated for the prevention of:

• Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin.
• Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation.

Dosage

• Emetogenic Chemotherapy

The recommended adult dosage of oral granisetron hydrochloride tablets is 2 mg once daily or 1 mg twice daily. In the 2 mg once-daily regimen, two 1 mg tablets are given up to 1 hour before chemotherapy. In the 1 mg twice-daily regimen, the first 1 mg tablet is given up to 1 hour before chemotherapy, and the second tablet 12 hours after the first. Either regimen is administered only on the day(s) chemotherapy is given. Continued treatment, while not on chemotherapy, has not been found to be useful.

• Radiation (Either Total Body Irradiation or Fractionated Abdominal Radiation)

The recommended adult dosage of oral granisetron hydrochloride tablets is 2 mg once daily. Two 1 mg tablets are taken within 1 hour of radiation. |offLabelAdultGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Granisetron (tablet) in adult patients.

|offLabelAdultNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Granisetron (tablet) in adult patients.

|fdaLIADPed=====Indications==== Granisetron hydrochloride tablets are indicated for the prevention of:

• Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin.
• Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation.

Dosage

• Emetogenic Chemotherapy

Safety and effectiveness in pediatric patients have not been established.

• Radiation (Either Total Body Irradiation or Fractionated Abdominal Radiation)

Safety and effectiveness in pediatric patients have not been established.

|contraindications=* Condition1

|warnings=* Description

Precautions

• Description

|clinicalTrials=There is limited information regarding Clinical Trial Experience of Granisetron (tablet) in the drug label.

Miscellaneous

|postmarketing=There is limited information regarding Postmarketing Experience of Granisetron (tablet) in the drug label.

Miscellaneous

|drugInteractions=* Drug

• Description

|useInPregnancyFDA=* Pregnancy Category |useInPregnancyAUS=* Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Granisetron (tablet) in women who are pregnant. |useInLaborDelivery=There is no FDA guidance on use of Granisetron (tablet) during labor and delivery. |useInNursing=There is no FDA guidance on the use of Granisetron (tablet) with respect to nursing mothers. |useInPed=There is no FDA guidance on the use of Granisetron (tablet) with respect to pediatric patients. |useInGeri=There is no FDA guidance on the use of Granisetron (tablet) with respect to geriatric patients. |useInGender=There is no FDA guidance on the use of Granisetron (tablet) with respect to specific gender populations. |useInRace=There is no FDA guidance on the use of Granisetron (tablet) with respect to specific racial populations. |useInRenalImpair=There is no FDA guidance on the use of Granisetron (tablet) in patients with renal impairment. |useInHepaticImpair=There is no FDA guidance on the use of Granisetron (tablet) in patients with hepatic impairment. |useInReproPotential=There is no FDA guidance on the use of Granisetron (tablet) in women of reproductive potentials and males. |useInImmunocomp=There is no FDA guidance one the use of Granisetron (tablet) in patients who are immunocompromised.

|administration=* Oral

• Intravenous

|monitoring=There is limited information regarding Monitoring of Granisetron (tablet) in the drug label.

• Description

|IVCompat=There is limited information regarding IV Compatibility of Granisetron (tablet) in the drug label.

|overdose====Acute Overdose===

Signs and Symptoms

• Description

Management

• Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Granisetron (tablet) in the drug label.

|drugBox= |mechAction=*

|structure=*

File:Granisetron (tablet)01.png

This image is provided by the National Library of Medicine.

|PD=There is limited information regarding Pharmacodynamics of Granisetron (tablet) in the drug label.

|PK=There is limited information regarding Pharmacokinetics of Granisetron (tablet) in the drug label.

|nonClinToxic=There is limited information regarding Nonclinical Toxicology of Granisetron (tablet) in the drug label.

|clinicalStudies=There is limited information regarding Clinical Studies of Granisetron (tablet) in the drug label.

|howSupplied=* |packLabel= |fdaPatientInfo=There is limited information regarding Patient Counseling Information of Granisetron (tablet) in the drug label.

|alcohol=* Alcohol-Granisetron (tablet) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

|brandNames=* ®

|lookAlike=* A® — B®

|drugShortage= }} {{#subobject:

 |Page Name=Granisetron (tablet)
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Granisetron (tablet)
 |Label Name=Granisetron (tablet)11.png

}}

{{#subobject:

 |Label Page=Granisetron (tablet)
 |Label Name=Granisetron (tablet)11.png

}}